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ABSTRACT
Spliceosome mutations are frequently observed in patients with myelodysplastic 
syndromes (MDS). However, it is largely unknown how these mutations contribute 
to the disease. MicroRNAs (miRNAs) are small noncoding RNAs, which have been 
implicated in most human cancers due to their role in post transcriptional gene 
regulation. The aim of this study was to analyze the impact of spliceosome mutations 
on the expression of miRNAs in a cohort of 34 MDS patients. In total, the expression 
of 76 miRNAs, including mirtrons and splice site overlapping miRNAs, was accurately 
quantified using reverse transcriptase quantitative PCR. The majority of the studied 
miRNAs have previously been implicated in MDS. Stably expressed miRNA genes for 
normalization of the data were identified using GeNorm and NormFinder algorithms. 
High-resolution melting assays covering all mutational hotspots within SF3B1, SRSF2, 
and U2AF1 (U2AF35) were developed, and all detected mutations were confirmed by 
Sanger sequencing. Overall, canonical miRNAs were downregulated in spliceosome 
mutated samples compared to wild-type (P = 0.002), and samples from spliceosome 
mutated patients clustered together in hierarchical cluster analyses. Among the 
most downregulated miRNAs were several tumor-suppressor miRNAs, including 
several let-7 family members, miR-423, and miR-103a. Finally, we observed that the 
predicted targets of the most downregulated miRNAs were involved in apoptosis, 
hematopoiesis, and acute myeloid leukemia among other cancer- and metabolic 
pathways. Our data indicate that spliceosome mutations may play an important role 
in MDS pathophysiology by affecting the expression of tumor suppressor miRNA genes 
involved in the development and progression of MDS. 
INTRODUCTION
Myelodysplastic syndromes (MDS) comprise a 
diverse group of clonal hematopoietic stem cell malignancies 
characterized by dysplasia, peripheral cytopenias, ineffective 
hematopoiesis, and risk of progression to acute myeloid 
leukemia (AML). It is the common understanding that 
MDS originates from a founding driver mutation within a 
cell having the capacity to differentiate into mature myeloid 
cells [1]. The nature of the founding mutation is likely to be 
involved in determining clinical phenotype and outcome. For 
instance, mutations in SF3B1 are strongly associated with 
refractory anemia with ring sideroblasts (RARS) and a good 
prognosis [2, 3], whereas SRSF2 and U2AF1 (U2AF35) 
mutations are mainly observed in refractory cytopenia with 
multi lineage dysplasia (RCMD) and refractory anemia 
with excess blasts (RAEB), and associated with high risk of 
leukemic transformation [4].
The founding mutation will eventually be present 
in almost all bone marrow cells due to the selective 
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advantage gained by the cell in which the mutation 
occurred. These clonal cells also carry hundreds of benign 
somatic passenger mutations captured at the start of clonal 
proliferation [5]. Most often the driver mutations are found 
in genes involved in RNA splicing, such as SF3B1, SRSF2, 
U2AF35, and ZRSR2 or in epigenetic regulation, such as 
TET2, DNMT3A, IDH1/2, ASXL1, and EZH2 [6–8]. As 
opposed to mutations in pro-apoptotic genes and growth 
signaling pathways these mutations do not, by themselves, 
promote clonal proliferation. However, they may affect 
the expression of a large number of downstream protein-
coding- and microRNA (miRNAs) genes, which lead to 
expansion of the mutated clone.
In addition to the genetic alterations observed in 
MDS, several miRNAs have been found to be aberrantly 
expressed in this disease [9]. Most miRNAs are processed 
through the canonical pathway involving the nuclease 
Drosha and its cofactor DGCR8. These canonical 
miRNAs may be located in intergenic regions or located 
within introns and exons of protein-coding genes and 
share their regulatory elements. However, some miRNAs 
are transcribed from the opposite strand in the reverse 
direction of the gene, which may lead to an inverse 
correlation between the expression of the gene and the 
miRNA [10]. In addition, an emerging number of miRNAs 
have recently been shown to bypass Drosha by utilizing 
the spliceosome instead. These are located within introns 
of protein encoding genes and are known as mirtrons when 
the 5′ and 3′ ends of the precursor miRNA transcript is 
defined by splice sites, and tailed mirtrons when either 
the 5′ or the 3′ end is defined by a splice site [11–13]. 
Thus, tailed mirtrons are processed by both splicing and 
exonuclease digestion. Finally, a competitive interaction 
between the splicing machinery and the Drosha/DGCR8 
complex has been discovered for miRNAs with precursors 
that are splice site overlapping (SO miRNAs) [14, 15].
Here, we studied the effects of spliceosome 
mutations on miRNA expression in primary bone 
marrow samples from MDS patients. To avoid potential 
confounding effects only patients with refractory anemia 
RA with or without ringsideroblasts were included in the 
study. High-resolution melting (HRM) assays covering 
all mutational hotspots of SF3B1, SRSF2, and U2AF35 
were developed. All mutations detected by HRM in the 
patient samples were subsequently confirmed by Sanger 
sequencing. In total, 76 miRNAs were studied, including 
intragenic and intergenic canonical miRNAs previously 
implicated in MDS, as well as mirtrons, tailed mirtrons, 
and SO miRNAs.
RESULTS
Spliceosome mutations in the patient samples
All patients were screened for mutations within 
SF3B1, SRSF2, and U2AF35 using HRM analysis. Since 
we observed a higher frequency of SF3B1 mutations than 
expected [6], the samples were also tested for mutations 
in SF3B1 using denaturing gradient gel electrophoresis 
(DGGE) analyses (data not shown). The results were 
100% concordant between the HRM and DGGE analyses, 
and all mutations were confirmed by Sanger sequencing 
(Supplementary Table S1, Figure 1). Twenty-two of the 
patients had a spliceosome mutation and 16 of these were 
found in SF3B1, five in SRSF2 and one in U2AF35. The 
mutations were unevenly distributed across RARS, RA, 
and del 5q subtypes. Among the patients with RARS 14 
out of 15 (93%) patients carried a mutation in SF3B1 and 
one carried a mutation in SRSF2 (7%). Among the patients 
with RA two out of 18 carried a mutation in SF3B1 (11%), 
four carried a mutation in SRSF2 (22%), and one carried 
a mutation in U2AF35 (6%). All mutations were mutually 
exclusive (Figure 2). Because SF3B1 mutations have 
a tendency to coexist with DNMT3A mutations [8] the 
samples were also screened for mutations within this gene 
(Supplementary Table S1, Supplementary Figure S1). In 
total, five of the patients carried a mutation in DNMT3A. 
Three of these patients also carried an SF3B1 mutation and 
one carried a mutation in SRSF2 (Figure 2).
Identification of accurate reference miRNA 
genes for the RT-qPCR analysis
For normalization of the miRNA expression data 
the identification of stably expressed reference genes 
are of paramount importance [16]. For this purpose we 
used the GeNorm and NormFinder algorithms [17, 18]. 
Data for 29 miRNAs and three commonly used reference 
genes (SNORD44, SNORD47, and RNU6B), which were 
expressed in all samples, were included in the analyses. 
Overall, there was a striking resemblance between the data 
obtained by the two algorithms (Supplementary Figure S2). 
The potential reference genes RNU6B, SNORD44, and 
SNORD47 were ranked ninth, 13th, and 22nd, respectively, 
by NormFinder, and 11th, 15th, and 21st, respectively, by 
GeNorm. Both algorithms identified miR-10b-5p and miR-
486-5p as the least stable genes, while miR-106b-3p was the 
most stable gene in both analyses. NormFinder identified 
miR-29a-3p and miR-130b-3p as the best combination of 
any two reference genes. These two miRNAs were also 
among the most stably expressed genes in the GeNorm 
analysis (Supplementary Figure S2). As NormFinder takes 
into account that different biological subgroups exists within 
the cohort, we decided to use the geometric mean of the Ct-
values for miR-29a-3p and miR-130b-3p when calculating 
relative expression quantities for each miRNA of interest.
Overall influences of spliceosome mutations on 
miRNA expression levels
When performing hierarchical clustering for all 
samples and miRNAs we observed that 14 out of 17 samples 
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clustering together contain a spliceosome mutation within 
SF3B1 or SRSF2 (Figure 3). This was unlikely to have 
happened by chance (P = 0.018). In addition, we observed 
that most mirtrons clustered together (P < 0.001). Sample 
15 clustered separately from all other samples as it had 
most miRNAs overexpressed, with the exception of miR-
145-5p, miR-146a-5p (located on chromosome 5q), miR-
125b-5p, miR-10a-5p, miR-10b-5p, and miR-27b-3p. 
This patient did not carry a spliceosome mutation or a 
mutation in DNMT3A, and was the youngest of all the 
patients in this cohort (Supplementary Table S1).
We also performed hierarchical clustering for 
each class of miRNA separately. Among the canonical 
miRNAs, we observed that 8 out of 12 samples clustering 
together contain an SF3B1 mutation in (Supplementary 
Figure S3). This was unlikely to have happened by chance 
(P = 0.04). When analyzing the mirtrons we observed 
that 11 out of 12 samples clustering together contain a 
spliceosome mutation (Supplementary Figure S4A). This 
was unlikely to have happened by chance (P = 0.01). No 
obvious clustering of spliceosome mutated samples could 
be observed when analyzing SO miRNAs (Supplementary 
Figure S4B).
Overall, canonical miRNAs were downregulated 
in spliceosome mutated samples versus wild-type MDS 
samples (P = 0.002), and there was a tendency for mirtrons 
to be downregulated as well (P = 0.11), while this was not 
the case for SO miRNAs (P = 0.63) (Figure 4A). Because 
each spliceosome mutation may have a different impact 
on the expression of miRNAs, SF3B1 mutated samples 
and SRSF2 mutated samples were analyzed separately. 
In SF3B1 mutated samples canonical miRNAs were 
downregulated (P = 0.004), and there was a tendency for 
mirtrons to be downregulated (P = 0.16), while SO miRNAs 
Figure 1: High-resolution melting assays for the detection of SF3B1, SRSF2, and U2AF35 mutations. Representative 
data for each of the hotspots are shown. (A) SF3B1 hotspot containing the N626D, R625G, and E622D detected in sample 10, 13, and 
28, respectively. (B) SF3B1 hotspot containing the K666R, K666T, and H662Q mutations detected in sample 3, 8, and 9, respectively. 
(C) SF3B1 hotspot containing the K700E mutation detected in sample 31. (D) SRSF2 hotspot containing the P95L and P95H mutations 
detected in sample 25 and 27, respectively. (E) U2AF35 hotspot containing the Q157R mutation detected in sample 23. (F) U2AF35 hotspot 
containing the S34 mutations not detected in any of the samples.
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were not (P = 0.44) (Figure 4B). Finally, it was observed 
that canonical miRNAs were downregulated in SRSF2 
mutated samples (P = 0.002), while mirtrons (P = 0.22) and 
SO miRNAs (P = 0.31) were not (Figure 4C).
Identification of differentially expressed miRNAs 
in spliceosome mutated samples
SF3B1 was the most frequently mutated gene and 
we decided to mainly focus on these mutations in the 
subsequent analyses. Several of the studied miRNAs were 
differentially expressed between wild-type samples and 
samples with SF3B1 mutations, and all were downregulated 
in the SF3B1 mutated samples. Most of these were canonical 
miRNAs, with the exception of one mirtron (miR-3605- 5p). 
Nine of the 10 canonical miRNAs were located in host 
genes. Furthermore, most of these miRNAs have previously 
been shown to have tumor suppressor properties (Table 1).
Hierarchical clustering was performed for the 
differentially expressed miRNAs, and the majority of 
the miRNAs were downregulated in the majority of the 
SF3B1 mutated samples (Figure 5). Sample 1 and 13 
were exceptions to this trend. Of note, sample 13 carried 
a DNMT3A mutation, and diverted the most from the 
other SF3B1 mutated samples. Interestingly, this sample 
clustered together with wild-type samples, and was the 
only sample carrying an R625G mutation.
Figure 2: Overview of the spliceosome and DNMT3A mutations detected in the MDS samples. (A) Distribution of the 
mutations detected in the RARS patients. (B) Distribution of the mutations detected in the RA and del 5q patient samples. (C) Number and 
nature of the mutations detected in individual patients of different subtype.
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Only five miRNAs (let-7a-5p, let-7b-5p, let-7c- 5p, 
miR-335-5p, and miR-4728-5p) were differentially 
expressed in SRSF2 mutated compared to wild-type 
MDS samples. Except for one mirtron (miR-4728-5p) 
all of these miRNAs were intragenic canonical miRNAs 
transcribed in the same direction as their host genes and 
downregulated in the mutated samples. Three of these 
miRNAs (let-7a-5p, let-7b-5p, and let-7c-5p) were also 
significantly downregulated in SF3B1 mutated samples 
relative to wild-type samples (Table 1). When considering 
all mutated samples together, eight miRNAs (let-7c-5p, 
let-7a-5p, let-7b-5p, miR-423-5p, let-7f-5p, miR-26b-
5p, miR-15a-5p, and miR-3605-5p) were differentially 
expressed compared to wild-type samples. Except for 
one mirtron (miR-3605-5p), all of these miRNAs were 
intragenic canonical miRNAs downregulated in the 
mutated samples. All of these were also significantly 
downregulated in SF3B1 mutated samples relative to 
wild-type samples, which is not surprising as most of the 
spliceosome mutated samples had an SF3B1 mutation.
Target and pathway analyses of the differentially 
expressed miRNAs
miRNA target predictions were performed for the 
differentially expressed miRNAs between wild-type 
samples and SF3B1 mutated samples. The miRNA target 
predictions of the differentially expressed miRNAs were 
compared to target predictions of the remaining miRNAs. 
These analyses revealed many putative oncogenes among 
the significantly enriched targets (See Supplementary 
Table S2), underscoring the notion that the differentially 
expressed miRNAs are tumor suppressors. 
Next, it was investigated which cellular processes 
and human diseases the significantly enriched predicted 
targets are involved in using the Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathway database. Several 
KEGG pathways related to MDS were found among the top 
significant hits (P < 0.001) including apoptosis, hematopoietic 
cell lineage, acute myeloid leukemia, JAK-STAT signaling 
pathway, spliceosome, MAPK signaling pathway, p53 
signaling pathway, chemokine signaling pathway, and 
several cancers. In addition, several metabolic pathways were 
found among the top hits including glutathione metabolism, 
beta-alanine metabolism, alanine, aspartate and glutamate 
metabolism, glycolysis/gluconeogenesis, amino sugar and 
nucleotide sugar metabolism, and citrate cycle (TCA cycle) 
(See Supplementary Table S3).
Host gene analyses
To investigate whether the observed downregulation 
of miRNAs could be a result of their respective host genes 
being downregulated each canonical miRNA was classified 
as intergenic or intragenic (Supplementary Figure S5A). 
Only one of the significantly downregulated miRNAs 
Table 1: Differentially expressed miRNAs between SF3B1 mutated patients and wild-type patients
MiRNA miRNA-class Chr. Host Gene Transcribed 
direction
LFC Tumor 
Suppressor
P-value
let-7c-5p Canonical 21 MIR99AHG Same −2.13 Yes 0.001
let-7b-5p Canonical 22 MIRLET7BHG Same −2.49 Yes 0.002
let-7f -5p −1.4 Yes 0.004
  let-7f-1 Canonical 9 JB153432 Same
  let-7f-2 Canonical x HUWE1 Same
let-7a-5p −1.67 Yes 0.005
  let-7a-1 Canonical 9 JB153432 Same
  let-7a-2 Canonical 11 MIRLET100 Same
  let-7a-3 Canonical 22 MIRLET7BHG Same
hsa-miR-423-5p Canonical 17 NSRP1 Same −1.66 Yes 0.007
hsa-miR-103a-3p −0.87 Yes 0.009
 hsa-miR-103a-1 Canonical 5 PANK3 Same
 hsa-miR-103a-2 Canonical 20 PANK2 Same
hsa-miR-26b-5p Canonical 2 CTDSP1 Same −2.24 Yes 0.011
let-7i-5p Canonical 12 No host gene N/A −1.09 Yes 0.011
hsa-miR-15a-5p Canonical 13 DLEU2 Same −1.18 Unknown 0.011
hsa-miR-3605-5p Mirtron 1 PHC2 Same −1.23 Unknown 0.030
hsa-miR-192-5p Canonical 11 AB429224 Same −0.84 Yes 0.047
Abbreviations, Chr: Chromosome, LFC: log2 fold change.
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Figure 3: Hierarchical clustering of the MDS patient samples and miRNAs. Each row represents a miRNA and each column 
represents a patient sample. Green indicates low expression relative to the mean expression level of the samples and red indicates high 
expression. The mutational status of each sample is indicated at the top. The miRNA class of each miRNA as well as differentially expressed 
miRNAs between wild-type MDS samples and SF3B1 mutated samples are indicated to the left. It is observed that 14 out of 17 samples 
containing a spliceosome mutation within SF3B1 or SRSF2 clustered together. Most of the miRNAs, which were differentially expressed 
between wild-type MDS samples and samples containing an SF3B1 mutation clustered together. Finally, all mirtrons except miR-4742-5p 
were found within the same cluster.
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was intergenic and, overall, there was no difference in 
expression between intergenic and intragenic miRNAs 
(P = 0.86) (Supplementary Figure S5B). Next, the 
expression of four host genes MIRLET7BHG, CTDSP1, 
PANK2, and PANK3 were measured. MIRLET7BHG is host 
gene for let-7b and CTDSP1 for miR-26b, while PANK2 
and PANK3 host miR-103a-2 and miR-103a-1, respectively. 
A weak but non-significant positive correlation between 
let-7b and MIRLET7BHG was observed (P = 0.08), while 
no correlations were observed between the expression of 
Figure 4: Volcano plots of the P-values and fold changes in expression of the miRNAs. Each miRNA is represented by 
a colored dot indicating its class. Blue represents canonical miRNA, red represents mirtron, and green represents SO miRNA. (A) 
Spliceosome mutated samples versus wild-type samples. It can be observed that all differentially expressed miRNAs were downregulated 
in the spliceosome mutated samples. (B) SF3B1 mutated samples versus wild-type samples. It can be observed that all differentially 
expressed miRNAs were downregulated in the samples containing an SF3B1 mutation. (C) SRSF2 mutated samples versus wild-type 
samples. It can be observed that all differentially expressed miRNAs were downregulated in the samples containing an SRSF2 mutation.
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CTDSP1 and miR- 26b and between PANK2 and PANK3 
and miR-103a (Supplementary Figure S6).
Validation of the custom plate miRNA data using 
single TaqMan assays
Individual cDNA syntheses were performed twice 
for all samples and analyzed by single TaqMan assays for 
the following miRNAs: let-7b, miR-10b-5p, miR-26b-5p, 
miR-29a-5p, miR-103-3p, miR-130b-3p, miR-145-5p, and 
miR-146a-5p. A high reproducibility of the raw Ct-values 
obtained after RT-qPCR performed on individual cDNA 
syntheses for each miRNA was observed (Supplementary 
Figure S7A). Furthermore, relatively good correlations 
were observed between the normalized data of the single 
TaqMan assays and the normalized data from the 96-well 
custom plate (Supplementary Figure S7B). Finally, all of 
these miRNAs were downregulated in patients with SF3B1 
mutations relative to wild-type patients as expected, with 
the exception of miR-10b-5p, which was also upregulated 
in the previous analysis (Supplementary Figure S8).
DISCUSSION
A high frequency of spliceosome mutations are 
observed in MDS [8]. Therefore, it is likely that abnormal 
RNA splicing plays an important role in MDS pathogenesis. 
Spliceosome mutations in MDS are generally gain-of-
function in nature, but little is known about their potential 
effects on the transcriptome [19]. It has, however, been 
shown that the vast majority of differentially expressed 
genes in SF3B1 mutated samples compared to wild-type 
samples are downregulated [20, 21]. This is likely due to 
the use of cryptic 3′ splice sites leading to retention of an 
intronic sequence containing in frame stop codons, which, in 
turn, may lead to nonsense-mediated mRNA decay (NMD) 
[20]. Alternatively, it may be due to key regulatory genes 
(e.g. encoding transcription factors or epigenetic modifiers) 
being aberrantly spliced. Splicing abnormalities of the 
epigenetic modifiers ASXL1 and EZH1, the transcription 
factor RUNX3, as well as the RAS pathway gene CBL have 
been observed in cases with SF3B1 mutations [21, 22]. 
Likewise, a splicing abnormality of RUNX1, a recurrently 
mutated transcription factor in MDS, has been observed in 
bone marrow cells from two cases with SRSF2 mutations, 
and aberrant splicing of the epigenetic modifier TET2 has 
been associated with mutations in U2AF35 [4]. In addition, 
SF3B1 mutations often coexist with mutations in DNMT3A 
[8], and for this reason it can be difficult to decipher the 
in vivo effects of each individual mutation.  
Our study is the first to analyze the impact of 
spliceosome mutations on the expression of miRNAs. 
We decided to focus on MDS as spliceosome mutations 
are common in this disease and on miRNAs since they 
play important roles in both solid and hematologic cancers 
[9, 23]. We studied a large panel of miRNAs, including 
intragenic and intergenic canonical miRNAs previously 
implicated in MDS, as well as mirtrons, tailed mirtrons, 
and SO miRNAs. To accurately quantify the expression 
of the miRNAs we used the GeNorm and NormFinder 
algorithms to identify stably expressed miRNA genes to 
normalize the RT-qPCR data. These two algorithms are 
inherently different, but can be expected to give similar 
results [24]. Indeed, we observed a striking similarity 
between the data obtained by each algorithm. Thus, the 
miRNA genes we identified to be stably expressed in MDS 
may be useful for normalization of RT-qPCR data in future 
miRNA studies. On the other hand, the commonly used 
references, SNORD44 and SNORD47, were not among the 
most stable genes in either of the analyses.
Figure 5: Hierarchical clustering of the MDS patient samples and differentially expressed miRNAs between wild-type 
samples and samples containing an SF3B1 mutation. Each row represents a miRNA and each column represents a patient sample. 
Green means low expression relative to the mean expression level of the samples and red means high expression. The mutational status of 
each sample is indicated at the top. It can be observed that the majority of the miRNAs were downregulated in the majority of the SF3B1 
mutated samples.
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Overall, our results show that miRNA expression 
is affected by spliceosome mutations in MDS. In line 
with the observations by Visconte and colleagues [21], 
we observed a strong association between spliceosome 
mutations and miRNA downregulation. In fact, we found 
none of the miRNAs to be significantly upregulated in 
SF3B1 or SRSF2 mutated samples compared to wild-
type samples. Because mutations within SF3B1 coexist 
with mutations in DNMT3A the observed miRNA 
downregulation could, in theory, be caused by altered 
methylation patterns of regulatory regions associated with 
the miRNAs and/or their host-genes. Thus, we tested all 
samples for mutations within DNMT3A. However, only 
three of the SF3B1 mutated samples carried a DNMT3A 
mutation, making it highly unlikely that DNMT3A 
mutations are responsible for the observed downregulation 
of miRNAs in the spliceosome mutated samples. 
Furthermore, two of the samples (patient 3 and 13), which 
carried both an SF3B1 mutation and a DNMT3A mutation, 
clustered together with wild-type samples. This cluster 
analysis also indicates that spliceosome mutations have 
an overall effect on the transcription of miRNAs, as most 
spliceosome mutated samples clustered together. Finally, 
it should be noted that the spliceosome is a very complex 
macromolecule consisting of numerous proteins and 
snRNAs [25], and it cannot be ruled out that wild-type 
samples carry a mutation in other spliceosome genes apart 
from the most commonly mutated studied here.
When analyzing each miRNA class separately 
it was observed that none of the SO miRNAs were 
significantly downregulated. This was expected since the 
Drosha/DGCR8 complex competes with the spliceosome 
machinery for processing of the precursor RNA molecule. 
Thus, it is likely that a mutated spliceosome is less 
competitive, leading to increased production of the 
miRNA and less production of the mRNA. However, as 
few SO miRNAs were expressed in the samples we were 
unable to make firm conclusions regarding the influence 
of spliceosome mutations on this group of miRNAs. On 
the other hand, it was expected that less efficient splicing 
would lead to decreased expression of mirtrons, which 
are directly dependent on the spliceosome for processing 
of the precursors. Indeed, it could be observed that most 
mirtrons were downregulated in spliceosome mutated 
samples compared to wild-type samples. However, we 
were surprised to observe that the spliceosome mutations 
had most profound effect on canonical miRNAs. 
Only two of the differentially expressed miRNAs in 
our study are directly processed by the spliceosome (miR-
3605-5p and miR-4728-5p), and we found an intergenic 
miRNA (let-7i-5p) to be significantly downregulated in the 
SF3B1 mutated samples. These observations point towards 
indirect mechanisms mainly being responsible for the 
aberrant expression of miRNAs in spliceosome mutated 
MDS. This could potentially be due to aberrant splicing 
of genes encoding transcription factors or epigenetic 
modifiers, which, in turn, may have an effect on the 
expression of miRNA host genes as well as miRNA genes 
having their own promotors. A weak but non-significant 
positive correlation between let7b and MIRLET7BHG 
(P = 0.08) was found, while no correlations were observed 
between the expression of CTDSP1 and miR- 26b and 
between PANK2 and PANK3 and miR-103a. It was, 
however, expected that correlations between PANK2 and 
PANK3 and miR-103a would be weaker as miR-103a 
has two genes, miR-103a-1 and miR-103a-2, located in 
PANK3 and PANK2, respectively. Furthermore, both genes 
have antisense transcripts, which may also influence the 
expression of the mature miRNA. Nevertheless, strong 
correlations between miRNAs and their host genes 
would not be expected as their half-lives are likely to 
be dissimilar and most host genes have several isoforms 
which may be differentially expressed.
Interestingly, we found several tumor suppressor 
miRNAs to be downregulated in patient samples with 
SF3B1 and SRSF2 mutations. Among these were several 
miRNAs belonging to the let-7 family, which are well 
known for their tumor suppressor activities [26, 27], 
and their essential role in stem cell differentiation and 
hematopoiesis [28]. In MDS let-7a has been shown to 
downregulate oncogenic KRAS and to be under-expressed 
in patients with intermediate or high-risk karyotype [29]. 
The miR-26 family is also involved in hematopoiesis [9], 
and miR-423-5p and miR-103a have previously been 
shown to be downregulated in MDS and to have tumor 
suppressor properties [30, 31]. Interestingly, a recent 
study highlighted that several genes involved in early 
hematopoiesis are aberrantly spliced in a model of mutant 
SRSF2 [32], including MEIS1 [33]. Thus our data suggest 
that the ineffective hematopoiesis observed in MDS not 
only results from aberrant splicing of protein encoding 
genes, but also from downregulation of miRNAs. 
When comparing the predicted targets of the 
differentially expressed miRNAs with the remaining 
miRNAs many putative oncogenes were among the 
significantly enriched targets. These included BACH1, 
a transcription factor, which is upregulated in several 
cancers and known to be regulated by the let-7 family 
[34], HMGA1, which is involved in cell differentiation 
and apoptosis and upregulated in several cancers [35], 
SLC4A4, which is upregulated in chronic myeloid 
leukemia stem cells [36], ZBTB5, which function as an 
oncogene by repressing the cell cycle arrest gene p21 
[37], and ACSL6, which has been shown to be part of 
a gene fusion in MDS and polycythemia vera [38, 39]. 
Overall, the significantly enriched predicted targets were 
found to be involved in apoptosis, hematopoiesis, acute 
myeloid leukemia, the JAK-STAT-, MAPK-, p53-, and 
chemokine signaling pathways, the spliceosome, and 
several cancers. In addition, several metabolic pathways 
were among the most significant pathways, which 
corresponds well with the recent finding that let-7a plays 
a prominent role in regulating energy metabolism in 
cancer cells [40].
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In conclusion, our study is the first to provide 
evidence that spliceosome mutations play an important 
role in MDS pathophysiology by affecting the expression 
of tumor suppressor miRNA genes involved in the 
development and progression of MDS.
MATERIALS AND METHODS
Patient samples
Ten mL of bone marrow (BM) were aspirated from 
the posterior iliac crest of 34 MDS patients at the time 
of diagnosis and three subjects with suspected MDS due 
to peripheral cytopenia, but without BM dysplasia or 
chromosomal abnormalities. The diagnoses of MDS were 
based on morphology supplemented by cytogenetics, and 
divided into subgroups according to WHO 2008 criteria.
Clinical and cytogenetic data of MDS patients can 
be found in Supplementary Table S1. 
The study was approved by the ethical committee 
for the Capital Region of Denmark (H-D-2009-003) 
and the Danish Data Protection Agency (30–1419) and 
conducted in accordance with the tenants of Helsinki.
Extraction of DNA and miRNA
DNA was purified from the mononuclear fraction of 
BM samples using the Gentra Puregene Cell Kit (Qiagen) 
according to the manufacturer’s instructions. miRNA was 
purified from Formalin-Fixed Paraffin Embedded (FFPE) 
whole BM biopsies using the Recover All Total Nucleic 
Acid Isolation Kit for FFPE (Ambion) according to the 
manufacturer’s instructions.
Mutation detection
HRM assays, covering mutations within SF3B1 (3 
hotspots), SRSF2 (1 hotspot), U2AF35 (2 hotspots) and 
DNMT3A (3 hotspots), were designed and optimized. 
DGGE assays, covering mutations within SF3B1 
(3 hotspots) were designed and optimized. All PCR primer 
sequences are shown in Supplementary Table S4. The nature 
of the mutations detected in the samples was confirmed 
using traditional Sanger sequencing of the PCR products. 
Additional information can be found in the Supplementary 
Files.
TaqMan miRNA 96-well custom plate design
The miRNA TaqMan assays used in this study 
were pre-spotted on a 96-well plate. In total, 67 canonical 
miRNAs, 11 mirtrons, and 11 SO miRNAs were included, 
together with four potential noncoding RNA reference 
genes. A background signal was detected for 17 assays, 
which were excluded from further analyses, yielding 
a total of 56 canonical miRNAs, nine mirtrons, 11 SO 
miRNAs, and three potential noncoding RNA reference 
genes. The miRNAs were selected following a literature 
search to ensure that the majority has been implicated in 
MDS previously. Details regarding each miRNA assay can 
be found in Supplementary Table S5.
RT-qPCR 
One-hundred ng of RNA from each patient sample 
were reverse transcribed with the TaqMan® MicroRNA 
Reverse Transcription Kit (Life Technologies) according to 
manufacturer’s instructions with a customized primer pool 
for all miRNA targets. The reactions were performed on a 
Veriti® 96-well Thermal Cycler (Applied Biosystems) with 
the following conditions: one cycle of 16°C for 30 min, 
42°C for 30 min, and 85°C for 5 min. Prior to qPCR the 
cDNA samples were pre-amplified using TaqMan® PreAmp 
Master Mix Kit (Applied Biosystems) according to the 
manufacturer’s instructions. The pre-amplification was 
performed on a Veriti® 96-well Thermal Cycler (Applied 
Biosystems) with the following conditions: one cycle of 
95°C for 10 min, 55°C for 2 min, 72°C for 2 min, 12 cycles 
of 95°C for 15 sec and 60°C for 4 min, and one cycle of 
99.9°C for 10 min. Subsequently, the samples were diluted 
1:10 in DNAse/RNAse free water. cDNA synthesis and 
pre-amplification were also performed on a no enzyme 
control (NEC) sample and a no template control (NTC). 
The qPCRs were performed using the TaqMan® Universal 
Master Mix II, no UNG Kit (Life Technologies) in a 96-well 
format, as described above, according to the manufacturer’s 
instructions on a StepOnePlus® Real-Time PCR System 
(Life Technologies). The following negative controls were 
included; the NEC and NTC from the cDNA synthesis, 
NTC from the pre-amplification and NTC at the qPCR level.
Host gene analyses
Single TaqMan assays were used for the host gene 
analysis. In total, four host genes and two reference genes 
were included in the study. In the RT-qPCR step ten ng of 
RNA from each patient sample were reverse transcribed 
with the TaqMan® MicroRNA Reverse Transcription 
Kit (Life Technologies) according to the manufacturer’s 
instructions with a primer pool for all target genes. The 
reactions were performed on a Veriti® 96-well Thermal 
Cycler (Applied Biosystems) as described above. Prior 
to qPCR the cDNA samples were pre-amplified using 
TaqMan® PreAmp Master Mix Kit (Applied Biosystems) 
according to the manufacturer’s instructions. The pre-
amplification was performed as described above using 
10 instead of 12 cycles of 95°C for 15 sec and 60°C for 
4 min. Subsequently, the samples were diluted 1:5 in 
DNAse/RNAse free water. The qPCRs were performed 
using the TaqMan® Universal Master Mix II, no UNG 
Kit (Life Technologies), according to the manufacturer’s 
instructions on a StepOnePlus® Real-Time PCR System 
(Life Technologies). The same negative controls as 
described above were included in these experiments.
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Validation of the custom plate miRNA data using 
single TaqMan assays
RT-qPCR was performed using single TaqMan 
assays (Life Technologies) for the following miRNAs; 
let-7b, miR-10b-5p, miR-26b-5p, miR-29a-5p, miR-103-
3p, miR-130b-3p, miR-145-5p, and miR-146a-5p. cDNA 
synthesis, pre-amplification, and qPCR were performed 
in duplicates for each patient sample. Ten ng of RNA 
were reverse transcribed using the TaqMan® MicroRNA 
Reverse Transcription Kit according to manufacturer’s 
instructions (Life Technologies). For pre-amplification all 
eight reverse transcription primers were pooled according 
to manufacturer’s instructions. The RT reaction was as 
described above. The pre-amplification was performed as 
described above using 10 instead of 12 cycles of 95°C 
for 15 sec and 60°C for 4 min. Subsequently, the samples 
were diluted 1:5 in DNAse/RNAse free water. The same 
negative controls as described above were included in 
these experiments.
Data and statistical analyses
Raw cycle threshold (Ct) values for miRNAs 
were extracted from the StepOnePlus® Real-Time PCR 
system (Applied Biosystems). Samples with an overall 
poor quality (geometric mean (Ctref genes) > 35) were 
excluded from further analyses. Therefore, it was not 
due to analysis failure when a sample did not amplify 
for a miRNA of interest, but rather it meant that the 
miRNA was not expressed in that sample. Accordingly, 
samples not amplifying for a given miRNA were given 
a Ct value of 40. Stably expressed reference genes were 
determined by importing Ct values transformed into a 
linear scale expression quantities, and raw Ct values 
into the NormFinder [17] and GeNorm algorithms [18], 
respectively. Data for 29 miRNAs and three commonly 
used reference genes (SNORD44, SNORD47, and 
RNU6B), which were expressed in all samples, were 
included in these analyses. For the NormFinder analysis 
three biological groups (wild-type controls, wild-type 
MDS, and spliceosome mutated MDS) were specified. 
miRNA expression data were analyzed with the qBase+ 
software, version 3.0 (Biogazelle) using the 2-ΔΔCt method 
[41], where ΔΔCt =  (Cttarget-Ctgeometric mean,ref genes)MDS sample 
-(Cttarget-Ctgeometric mean,ref genes)mean of control samples. One-sided 
Fisher’s exact tests were used to evaluate if specific 
clusters were enriched for a given type of sample of 
miRNA. Differences in miRNA expression between 
spliceosome mutated samples and wild-type samples 
were evaluated with a Mann-Whitney U test. Overall 
differences in miRNA expression between spliceosome 
mutated samples and wild-type samples were evaluated 
with a Wilcoxon signed-rank test. For the cluster analyses 
miRNAs were excluded from the analyses when more 
than 1/3 of the samples did not amplify. In total, less 
than five percent of the data points in the unsupervised 
cluster analysis were derived from samples which did not 
amplify. The Z-transformed miRNA expression levels 
were subjected to complete-linkage hierarchical clustering 
using the Pearson distance metric. miRNA target 
predictions were retrieved from TargetScan [42], PicTar 
[43], miRanda [44], and StarMirDB [45] and integrated 
to improve the precision of the predictions using the 
same strategy as in STRING [46]. The top 0.1% of the 
integrated predictions (~100 targets per miRNA) was used 
to infer enriched targets and associated KEGG pathway 
database terms (http://www.genome.jp/kegg/pathway.
html) of the differentially expressed miRNA between 
samples with SF3B1 mutations compared to wild-type 
samples. Enrichments were evaluated using the Fisher’s 
exact test and the Benjamini and Hochberg correction for 
multiple testing. 
For the host gene analysis, the RT-qPCR data were 
analyzed as described above, using the mean Ct value of 
two reference genes (UBC and JUNB). Goodness-of-fit 
linear regression was used to evaluate possible relations 
between expression of the host genes and the miRNAs 
using Prism 6 (GraphPad software, San Diego, CA, 
USA), which employs an F test to evaluate if the slope is 
significantly different from zero.
For the validation analysis, the RT-qPCR data 
were analyzed as described above, using the mean Ct 
value of the two replicates for each miRNA. However, 
samples with a standard deviation above two for any 
of the reference miRNA genes were excluded from the 
analysis of differentially expressed miRNAs (this applied 
to sample 18, 23, 29, and 31). Goodness-of-fit linear 
regression was used to evaluate possible relations between 
expression of the host genes and the miRNAs using Prism 
6 (GraphPad).
Any differences were considered to be statistically 
significant when the P-value was < 0.05.
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